Are cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting predicted by residual platelet reactivity to ADP detected by a point-of-care assay : a 12-month follow-up?
RPR to ADP with clopidogrel therapy, measured by the point-of-care assay VerifyNow P2Y12, is able to detect acute coronary syndrome patients at risk of 12-month cardiovascular death and nonfatal MI. The optimal cutoff value was identified as being 240 P2Y12 reaction units.
At the population level, evening chronotype was independently associated with diabetes, metabolic syndrome, and sarcopenia. These results support the importance of circadian rhythms in metabolic regulation.